Status:
COMPLETED
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
Lead Sponsor:
Peking University People's Hospital
Conditions:
Bone Sarcoma
Soft Tissue Sarcoma
Eligibility:
All Genders
Brief Summary
This multicenter retrospective study assessed the efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after several lines of TKIs' resistance.
Detailed Description
The short-lived duration of disease control and secondary drug resistance have posed a threat to the effect of TKIs. Fruquintinib is a novel TKI with a high selectivity of VEGFR-1,2,3 without metaboli...
Eligibility Criteria
Inclusion
- Histologically confirmed bone or soft tissue sarcomas;
- Progressed after several lines of therapy;
- Previously treated with other TKIs before fruquintinib;
- Received fruquintinib-based treatment;
- Measurable lesions according to the Response Evaluation Criteria for Solid Tumors (RECIST) version1.1;
- Eastern Cooperative Oncology Group (ECOG) performance status ≤3
Exclusion
- Failure to complete regular follow-up after administration.
- Discontinued the fruquintinib-based treatment due to neither progression nor unacceptable toxicity.
Key Trial Info
Start Date :
November 25 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 15 2023
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT06202599
Start Date
November 25 2021
End Date
November 15 2023
Last Update
January 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044